How effective is crizotinib in ROS1 patients?

ROS1gene rearrangement is a unique molecular change in non-small cell lung cancer. Similar to ALKgene rearrangement, it is also a driver gene mutation that can lead to abnormal proliferation of cancer cells. As a tyrosine kinase inhibitor, crizotinib can inhibit the abnormal kinase activity caused by ROS1 gene rearrangement, thereby achieving therapeutic purposes.

In multiple clinical trials, crizotinib has performed well in treating ROS1 patients with ORR. Specifically, its ORRrange is roughly between 54% and 80%. This means that more than half of the patients had their tumors significantly shrunk or controlled after receiving crizotinib.

In addition to highORR, crizotinib significantly prolonged ROS1 positive patients' PFS and OS. In clinical trials, the median PFS of patients treated with crizotinib ranged from 5 to 20 months, and the median OS reached 32.5 to 51.4 months. These data fully demonstrate the superior performance of crizotinib in prolonging patient survival.

Crizotinib was well tolerated, and most patients successfully completed the treatment cycle. Although some adverse reactions may occur during use, such as nausea, vomiting, diarrhea, etc., these are mild and controllable. These side effects are well tolerated by patients with appropriate dosage adjustments and supportive care.

It is worth noting that approximately 40% of ROS1positive late-stage NSCLC patients have brain metastases at the time of initial diagnosis. Although crizotinib is effective in NSCLC with brain metastasisPatient efficacy is relatively limited, but it still provides a treatment option for this subset of patients. In some cases, crizotinib can slow the progression of brain metastases and improve patients' quality of life.

Although crizotinib has achieved remarkable results in the treatment ofROS1positiveNSCLC, the problem of drug resistance remains a challenge. Long-term use of crizotinib may cause cancer cells to develop drug-resistant mutations, reducing the drug's effectiveness. In order to solve this problem, researchers are actively exploring strategies such as combination drug use and sequential treatment to overcome drug resistance.